The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform
Richard Casey - One of the best experts on this subject based on the ideXlab platform.
-
vardenafil improves patient satisfaction with erection hardness orgasmic function and overall Sexual Experience while improving quality of life in men with erectile dysfunction
The Journal of Sexual Medicine, 2004Co-Authors: Craig F Donatucci, Marc Gittelma, Terry A Taylo, Marc Thibonnie, Keith Angerte, Richard CaseyAbstract:ABSTRACT Purpose The North American Pivotal Trial was designed to investigate the efficacy and safety of vardenafil in males with erectile dysfunction (ED). Materials and Methods In this randomized, double‐blind, placebo‐controlled, multicenter, fixed‐dose, parallel group, 6‐month study, vardenafil at three doses (5 mg, 10 mg, and 20 mg) was compared to placebo with the primary efficacy variables being the International Index of Erectile Function (IIEF) Erectile Function (EF) domain score and per patient diary response success rates for penetration and maintenance of erection through completion of intercourse. Additional efficacy variables included IIEF domain scores measuring intercourse satisfaction, orgasmic function, Sexual desire, and overall satisfaction. Diary entries for overall per patient satisfaction rates for hardness and Sexual Experience were also measured. Improvements in quality of Sexual life were assessed using the Fugl‐Meyer quality of life (QoL) questionnaire. Results Compared to placebo, patients taking 10 mg and 20 mg doses of vardenafil showed statistically significantly greater improvement in IIEF domain scores measuring intercourse satisfaction (10.3 and 10.3 vs. 7.7), orgasmic function (7.1 and 6.9 vs. 5.3), overall satisfaction. (7.1 and 7.1 vs. 5.2) for vardenafil 10 mg and 20 mg vs. placebo, respectively, at last observation carried forward (LOCF). Vardenafil 5 mg was statistically significantly better than placebo for the secondary IIEF domain variables of intercourse satisfaction (8.9 vs. 7.7) and overall satisfaction (6.3 vs. 5.2) for vardenafil vs. placebo, respectively, at LOCF. Per patient satisfaction rates for the secondary diary variables measuring erection hardness (38%, 52%, 58% and 18%) and overall satisfaction (45%, 58%, 62% and 23%) were dose dependent and statistically significantly superior for vardenafil at 5 mg, 10 mg and 20 mg compared with placebo, respectively. Patients’ answers to the Fugl‐Meyer QoL questionnaire assessing improvement in Sexual life also indicated statistically significant superiority for all doses of vardenafil vs. placebo treatment. The most frequent adverse events (AE) in the 5 mg, 10 mg, and 20 mg of vardenafil and placebo groups, respectively, were: headache (10%, 22%, 21% and 4%), flushing (5%, 10%, 13% and 0%), dyspepsia (1%, 4%, 6% and Conclusion Vardenafil was superior to placebo for IIEF domain scores, per patient success rates for diary questions, and assessment of quality of Sexual life, in a broad range of patients with ED irrespective of etiology or severity. Vardenafil was generally well tolerated, with most AEs being mild or moderate in severity and transient in nature.
Marc Thibonnie - One of the best experts on this subject based on the ideXlab platform.
-
vardenafil improved patient satisfaction with erectile hardness orgasmic function and Sexual Experience in men with erectile dysfunction following nerve sparing radical prostatectomy
The Journal of Urology, 2005Co-Authors: Ajay Nehra, Marc Thibonnie, Joh Grantmyre, Andrea Nadel, Gerald OckAbstract:ABSTRACTPurpose:: Nerve sparing radical retropubic prostatectomy (NS-RRP) results in erectile dysfunction in a significant number of patients. Vardenafil, a potent and selective phosphodiesterase type 5 inhibitor, is generally safe. It improves International Index of Erectile Function erectile function domain scores, and penetration and erection maintenance success rates in patients who have undergone NS-RRP. We report additional parameters important to patient perceptions regarding erection quality and satisfaction with Sexual Experience following NS-RRP.Materials and Methods:: A total of 440 men at 58 centers throughout the United States and Canada participated in this randomized, placebo controlled, double-blind trial with 3 phases, namely baseline (4-week untreated period), treatment (12 weeks) and followup (7 days). Participants received placebo (145), 10 mg vardenafil (146) or 20 mg vardenafil (149) at home on demand but no more than once per calendar day. Efficacy and satisfaction with erection qua...
-
vardenafil improves patient satisfaction with erection hardness orgasmic function and overall Sexual Experience while improving quality of life in men with erectile dysfunction
The Journal of Sexual Medicine, 2004Co-Authors: Craig F Donatucci, Marc Gittelma, Terry A Taylo, Marc Thibonnie, Keith Angerte, Richard CaseyAbstract:ABSTRACT Purpose The North American Pivotal Trial was designed to investigate the efficacy and safety of vardenafil in males with erectile dysfunction (ED). Materials and Methods In this randomized, double‐blind, placebo‐controlled, multicenter, fixed‐dose, parallel group, 6‐month study, vardenafil at three doses (5 mg, 10 mg, and 20 mg) was compared to placebo with the primary efficacy variables being the International Index of Erectile Function (IIEF) Erectile Function (EF) domain score and per patient diary response success rates for penetration and maintenance of erection through completion of intercourse. Additional efficacy variables included IIEF domain scores measuring intercourse satisfaction, orgasmic function, Sexual desire, and overall satisfaction. Diary entries for overall per patient satisfaction rates for hardness and Sexual Experience were also measured. Improvements in quality of Sexual life were assessed using the Fugl‐Meyer quality of life (QoL) questionnaire. Results Compared to placebo, patients taking 10 mg and 20 mg doses of vardenafil showed statistically significantly greater improvement in IIEF domain scores measuring intercourse satisfaction (10.3 and 10.3 vs. 7.7), orgasmic function (7.1 and 6.9 vs. 5.3), overall satisfaction. (7.1 and 7.1 vs. 5.2) for vardenafil 10 mg and 20 mg vs. placebo, respectively, at last observation carried forward (LOCF). Vardenafil 5 mg was statistically significantly better than placebo for the secondary IIEF domain variables of intercourse satisfaction (8.9 vs. 7.7) and overall satisfaction (6.3 vs. 5.2) for vardenafil vs. placebo, respectively, at LOCF. Per patient satisfaction rates for the secondary diary variables measuring erection hardness (38%, 52%, 58% and 18%) and overall satisfaction (45%, 58%, 62% and 23%) were dose dependent and statistically significantly superior for vardenafil at 5 mg, 10 mg and 20 mg compared with placebo, respectively. Patients’ answers to the Fugl‐Meyer QoL questionnaire assessing improvement in Sexual life also indicated statistically significant superiority for all doses of vardenafil vs. placebo treatment. The most frequent adverse events (AE) in the 5 mg, 10 mg, and 20 mg of vardenafil and placebo groups, respectively, were: headache (10%, 22%, 21% and 4%), flushing (5%, 10%, 13% and 0%), dyspepsia (1%, 4%, 6% and Conclusion Vardenafil was superior to placebo for IIEF domain scores, per patient success rates for diary questions, and assessment of quality of Sexual life, in a broad range of patients with ED irrespective of etiology or severity. Vardenafil was generally well tolerated, with most AEs being mild or moderate in severity and transient in nature.
Angelita Lee - One of the best experts on this subject based on the ideXlab platform.
-
p584 factors predicting lifetime Sexual Experience among rural reservation based native american youth
Sexually Transmitted Infections, 2019Co-Authors: Lauren Tingey, Rachel Chambers, Summer Rosenstock, Anne Rompalo, Anna Beach, Laura Melgar, Angelita LeeAbstract:Background Early Sexual initiation is a risk factor for Sexually transmitted infection and unintended pregnancy. Native American youth initiate sex earlier than other U.S. youth contributing to current inequalities in Sexual health. Identifying factors that predict lifetime Sexual Experience among Native youth can inform the development of primary prevention programming to delay Sexual initiation and improve Sexual health outcomes in this population. Methods We analyzed cross-sectional data from 558 Native youth ages 11–19 from a rural, reservation-based community. Multivariate logistic regression models were used to estimate associations between lifetime Sexual Experience (vaginal and/or anal sex) and independent variables across eight categories: sociodemographic, knowledge, attitudes/perceptions, beliefs, intentions, skills, behaviors, and theoretical constructs. Results The sample was 51.6% female, mean age 13.4 years (SD=1.9); and 8.0% were Sexually Experienced. In our final model, older age (OR=2.04; p Conclusion Results provide direction for future programming. Programs focusing on intentions to have sex while cultivating skills to promote condom use, in addition to being delivered stratified by age, may have the greatest impact. Substance use was a driving factor in Sexual initiation; thus, Sexual health education programs should simultaneously target substance use prevention. That identifying as transgendered predicted Sexual Experience is notable: despite research indicating transgendered youth of other ethnicities have heightened risk for negative Sexual health outcomes, little research has been conducted with transgendered Native youth. Disclosure No significant relationships.
-
risk and protective factors associated with lifetime Sexual Experience among rural reservation based american indian youth
The Journal of Primary Prevention, 2018Co-Authors: Lauren Tingey, Rachel Chambers, Summer Rosenstock, Francene Larzelere, Novalene Goklish, Angelita Lee, Anne RompaloAbstract:Early Sexual initiation is a catalyst for Sexually transmitted infection and unintended pregnancy. American Indian/Alaska Native (AI/AN) youth initiate sex prior to age 13 more often than other U.S. youth, contributing to current inequalities in Sexual health. Identifying what factors were associated with lifetime Sexual Experience among AI/AN youth can inform the development of primary prevention programming to delay Sexual initiation, alleviate the costs of early Sexual activity, and improve Sexual health outcomes in this population. We analyzed cross-sectional data from 267 AI youth ages 13–19, recruited from a rural, reservation-based community. We used multivariate logistic regression models to estimate associations between independent variables and lifetime Sexual Experience (vaginal and/or anal sex) across the following categories: sociodemographic, knowledge, attitudes/perceptions, beliefs, intentions, skills, behaviors, and theoretical constructs. The sample was 56.2% female, mean age 15.1 years (SD = 1.7), and 22.5% were Sexually Experienced. In our final model, condom use self-efficacy (attitude/perception factor) and intentions to remain abstinent until marriage (intention factor) were associated with lower odds of lifetime Sexual Experience. Age (sociodemographic factor), intention to have sex (intention factor), use of any contraception (behavior factor), and higher response efficacy (theoretical construct) were associated with lifetime Sexual Experience. Of these, intention to have sex was the strongest indicator. These results both corroborate and contrast with other research conducted among rural, reservation-based AI/AN youth. Our findings show programs targeting intentions may have the greatest impact among reservation-based AI youth, and justify program delivery stratified by age group in this setting.
Gerald Ock - One of the best experts on this subject based on the ideXlab platform.
-
vardenafil improved patient satisfaction with erectile hardness orgasmic function and Sexual Experience in men with erectile dysfunction following nerve sparing radical prostatectomy
The Journal of Urology, 2005Co-Authors: Ajay Nehra, Marc Thibonnie, Joh Grantmyre, Andrea Nadel, Gerald OckAbstract:ABSTRACTPurpose:: Nerve sparing radical retropubic prostatectomy (NS-RRP) results in erectile dysfunction in a significant number of patients. Vardenafil, a potent and selective phosphodiesterase type 5 inhibitor, is generally safe. It improves International Index of Erectile Function erectile function domain scores, and penetration and erection maintenance success rates in patients who have undergone NS-RRP. We report additional parameters important to patient perceptions regarding erection quality and satisfaction with Sexual Experience following NS-RRP.Materials and Methods:: A total of 440 men at 58 centers throughout the United States and Canada participated in this randomized, placebo controlled, double-blind trial with 3 phases, namely baseline (4-week untreated period), treatment (12 weeks) and followup (7 days). Participants received placebo (145), 10 mg vardenafil (146) or 20 mg vardenafil (149) at home on demand but no more than once per calendar day. Efficacy and satisfaction with erection qua...
James G. Pfaus - One of the best experts on this subject based on the ideXlab platform.
-
behavioral defeminization by prenatal androgen treatment in rats can be overcome by Sexual Experience in adulthood
Hormones and Behavior, 2015Co-Authors: Sherri Lee Jones, E Cordeaux, K Germe, James G. PfausAbstract:Abstract Exposure to testosterone during a critical period of prenatal development disrupts the normal display of Sexual behaviors in adult ovariectomized (OVX) rats treated with estradiol benzoate (EB) followed by progesterone (P). The organizational hypothesis posits that prenatally androgenized females (PNAFs) are desensitized to EB. We tested this hypothesis by first treating PNAFs with varying doses of EB (2.5, 5, 10, 20 μg) followed by P (500 μg), and second by subjecting females to an established EB behavioral sensitization paradigm where females are first given Sexual Experience with EB (10 μg) and P prior to repeated Sexual behavior testing with EB alone. Long-Evans females were androgenized in utero by a s.c. injection of 500 μg testosterone propionate or the oil control to pregnant dams on gestational day 18. Female offspring were OVX on postnatal day 80 and tested one week later in the unilevel 4-hole pacing chamber. Genital tissue was defeminized in PNAFs, and the lordosis quotient (LQ) and partial (i.e., hops/darts) and full solicitations were significantly lower, while defensive behaviors were higher, in PNAF females, relative to non-PNAF females regardless of the acute EB priming dose. However, repeated testing with EB alone (10 μg), or EB and P eliminated the differences between groups on LQ and hops/darts, indicating that the behavioral deficit can be overcome by Sexual Experience. These results suggest that PNAFs are not desensitized to EB, and despite disruptions in Sexual differentiation of anatomical structures, the deficiency in Sexual behavior in response to acute EB and P can be experientially overcome. PNAFs appear, however, to have a chronic deficit in the expression of full solicitations.
-
the role of oxytocin and vasopressin in conditioned mate guarding behavior in the female rat
Physiology & Behavior, 2015Co-Authors: Amanda Holley, Kerstin Wenzel, Sieger Roorda, Shannon Bellevue, Daniel Vosberg, James G. PfausAbstract:Abstract We have shown previously that female rats given their first copulatory Experiences with the same male rat display mate guarding behavior in the presence of that male provided a female competitor is also present. Females given access to the familiar male show more Fos induction within regions of the brain that contain oxytocin (OT) and vasopressin (AVP) cell bodies, notably the supraoptic (SON) and paraventricular nuclei (PVN) relative to females given Sexual Experience with different males. The present experiments examined whether the Fos induction we previously observed within the SON and PVN occurred within OT and/or AVP neurons, and whether exogenous administration of OT or AVP prior to female rats first Sexual Experience could potentiate the acquisition of mate guarding behavior. Female rats that display conditioned mate guarding had significantly more double-labeled Fos/OT neurons in both SON and PVN, and significantly more Fos/AVP neurons in the PVN. Peripheral administration of OT or AVP prior to their first Sexual Experience with the familiar male facilitated different aspects of mate guarding: OT augmented affiliative behaviors and presenting responses whereas AVP augmented interference behavior. These results indicate that female rats' first Experiences with Sexual reward when paired with the same male induce changes to bonding networks in the brain. Moreover peripheral administration of OT or AVP during their first Sexual Experience can augment different aspects of mate guarding behavior.
-
who what where when and maybe even why how the Experience of Sexual reward connects Sexual desire preference and performance
Archives of Sexual Behavior, 2012Co-Authors: James G. Pfaus, Tod E. Kippin, Genaro A Coriaavila, Helene Gelez, Veronica M Afonso, Nafissa Ismail, Mayte ParadaAbstract:Although Sexual behavior is controlled by hormonal and neurochemical actions in the brain, Sexual Experience induces a degree of plasticity that allows animals to form instrumental and Pavlovian associations that predict Sexual outcomes, thereby directing the strength of Sexual responding. This review describes how Experience with Sexual reward strengthens the development of Sexual behavior and induces Sexually-conditioned place and partner preferences in rats. In both male and female rats, early Sexual Experience with partners scented with a neutral or even noxious odor induces a preference for scented partners in subsequent choice tests. Those preferences can also be induced by injections of morphine or oxytocin paired with a male rat’s first exposure to scented females, indicating that pharmacological activation of opioid or oxytocin receptors can “stand in” for the Sexual reward-related neurochemical processes normally activated by Sexual stimulation. Conversely, conditioned place or partner preferences can be blocked by the opioid receptor antagonist naloxone. A somatosensory cue (a rodent jacket) paired with Sexual reward comes to elicit Sexual arousal in male rats, such that paired rats with the jacket off show dramatic copulatory deficits. We propose that endogenous opioid activation forms the basis of Sexual reward, which also sensitizes hypothalamic and mesolimbic dopamine systems in the presence of cues that predict Sexual reward. Those systems act to focus attention on, and activate goal-directed behavior toward, reward-related stimuli. Thus, a critical period exists during an individual’s early Sexual Experience that creates a “love map” or Gestalt of features, movements, feelings, and interpersonal interactions associated with Sexual reward.
